Look back at pharma news in week to November 16

18 November 2018

By Barbara Obstoj-Cardwell. Editor

Clinical trials news last week included Amarin’s presentation of new data on its Vascepa, showing strong cardiovascular risk reduction which caused controversy. Also, Merrimack announced that it would discontinue its cancer drug MM-121 following disappointing results, and AstraZeneca suffered a setback with another MYSTIC trial of lung cancer drug Imfinzi. On the deal making front, AstraZeneca featured as it continues to sell off non-core assets, this time its respiratory drug Synagis to Swedish Orphan Biovitrum (Sobi), while Arena Pharmaceuticals inked a licensing deal with United Therapeutics for its pulmonary arterial hypertension (PAH) drug ralinepag worth a potential $1.2 billion.

Amarin’s Vascepa trial stirs debate as stock drops

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK